Gene Technology in Tissue Engineering

1Xiao-Dan Sun and 2In-Seop Lee

1Laboratory of Advanced Materials, Department of Materials Science & Engineering, Tsinghua University, Beijing 100084, China
2Institute of Physics & Applied Physics, and Atomic-scale Surface Science Research Center, Yonsei University, Seoul 120-749, Korea

Abstract: Scaffold, cells and signaling factors are regarded as the three essential components in tissue engineering. With the development of molecular and cell biology, gene technology is beginning to show a promising position in tissue engineering as it can influence these essential components at DNA-level. By introducing plasmid DNA or genes encoding certain signaling factors (growth factors/cytokines) into the cells, required growth factors/cytokines can be expressed and secreted spatially and temporally by the transfected cells, which will promote the differentiation, proliferation and organization of the cells on the scaffold. Protein-based scaffolds which have specific structures can also be prepared genetically to induce attachment and spreading of the cells. This paper reviews research work of gene technology developed in tissue engineering.

Key words: Gene engineering, tissue engineering, molecular biology, cell biology

1. INTRODUCTION

Tissue engineering refers to the science of generating new living tissues to replace, repair or augment the diseased/damaged tissue and restore tissue/organ function [1]. Regardless of the preparation technique, tissue engineering requires at least three key components, which are scaffold/matrix to support cells for the tissue formation, responsive cells to produce cellular and extracellular matrix and growth-inducing stimulus factors (signaling factors) to promote the division, maturation and differentiation of the cells [2-4]. Accordingly, the improvement of scaffold design, spatiotemporal delivery/release of signaling factors and subsequent cell proliferation remain the challenges of tissue engineering.

With the development of cell biology and molecular biology, gene technology represents a promising method to meet these challenges of tissue engineering applications in several different ways by controlling the synthesis of the scaffolds or the secretion of the signaling factors at DNA-level (Figure 1). New fields of ‘gene-enhanced tissue engineering’ (Route 1 and 2 in Figure 1) [5-8] and ‘genetically engineered protein-based polymers’ (Route 3 in Figure 1) [9] have emerged as attractive subjects in tissue engineering. In this review, we will summarize some work in these developing fields to show the potentially promising prospects of the combination between tissue engineering and gene technology.

2. GENE-ENHANCED TISSUE ENGINEERING

The most common approach to tissue engineering is to seed cells derived from either biopsies or stem cells on biodegradable scaffolds configured to the shape of the new tissue in vitro, and then implant the cell-seeded scaffolds into the patient subsequently when the cells are differentiated and proliferated to certain extent [10]. Additionally, the presence of high and sustained levels of signaling factors has been demonstrated to be one of the most important factors for in vivo healing since the motility, differentiation, organization, proliferation and apoptosis of the cells associated with tissue formation are greatly influenced by soluble (e.g. cytokines) and insoluble (e.g. ECM proteins) factors in the local microenvironment [11, 12]. The most obvious

Corresponding Author: In-Seop Lee, Institute of Physics & Applied Physics, and Atomic-scale Surface Science Research Center, Yonsei University, Seoul 120-749, Korea
means of delivering these signaling factors (growth factors or cytokines) \textit{in situ} is direct application of the recombinant protein \cite{13}. However, most growth factors are rapidly cleared and have half-lives of minutes \cite{12}, and dosage of milligram amounts of recombinant cytokine is required to show significant efficacy advantages, which is expensive to manufacture and presents an additional safety risk \cite{5}. Thereby, the ability to regulate expression of desired signaling factors in time and space may be critical to the engineering of complex tissue architectures. On this occasion, ‘gene-enhanced tissue engineering’ has turned up to be a promising way to provide sustained delivery of growth factor/cytokine to a local site \textit{in vivo}. An important assumption herein was that, following gene transfer, the recombinant cytokine would be expressed at more nearly physiological levels but for a prolonged period of time by local transfected cells.

### 2.1. Categories of Gene-Enhanced Tissue Engineering

Gene-enhanced tissue engineering deals with the scientific and technologic endeavors to produce cultured cells or polymer matrices transduced with defined gene vectors encoding certain signaling factors by means of genetic engineering technique, to make transduced cells or gene activated matrices (GAM) highly express corresponding cytokines/growth factors into the microenvironment, and then to enhance the differentiation and proliferation abilities of the cells to finally construct artificial tissue with desired functions \cite{14}.

Gene-enhanced tissue engineering can be divided into two categories according to the approaches for the gene transfer, which are \textit{ex vivo} approach and \textit{in vivo} approach \cite{2,14,15}. The \textit{ex vivo} approach illustrated in Route ① in Figure 1 consists of isolating cells from a tissue biopsy, transferring a defined gene/plasmid DNA encoding required signaling factors into cells using viral or non-viral vectors and growing cells in culture for them to be transrected or transduced \textit{in vitro} before the cells are seeded into the matrix and the cell-supplemented matrix is finally implanted into the patient. The alternative \textit{in vivo} approach illustrated in Route ② in Figure 1 consists of directly injecting gene-vector or implanting the gene–supplemented matrix to relevant position to transduce the cells \textit{in situ} by the delivery and release of the gene/plasmid DNA within the patient. In both approaches, the expression and secretion of desired signaling factors by the transduced cells are expected to stimulate and enhance the survival, proliferation or function of particular populations of cells in return.

Up to now, the \textit{ex vivo} approach is presented to be safe and effective, while the techniques are complicated since it requires appropriate cell sourcing and potentially more intensive surgical procedures, such as harvesting of autologous cells or implantation of cell–scaffold constructs \cite{16}. On the other hand, the \textit{in vivo} approach is attractive because of its technical simplicity such as the controlled releasing of DNA. However, the \textit{in vivo} approach is presently limited by the demonstration of both safety and biological efficacy \cite{15}. It has great potential to be used in the setting of inherited genetic defects and in tissues that consist of relatively homogeneous long-lived cells and in which phenotypic expression may be induced and durably maintained by expression of a single gene \cite{17}.

### 2.2. Applications of Gene-Enhanced Tissue Engineering

Since 1993, Bonadio’s research group has explored the possibility that cytokines and growth factors were delivered not as recombinant proteins but as plasmid-genes \cite{18}. Till now, as a means of delivering growth factors or cytokines with cells in a scaffold to the sites of tissue injury to accelerate and/or induce a natural biological regeneration, gene technology has been developed in tissue engineering for many tissues and organs such as bone \cite{4,15,19}, cartilage \cite{20,22}, tendon, ligament \cite{23,24}, muscle \cite{2}, heart \cite{25,26}, skin \cite{27,28}, neuron \cite{28} and \textit{et al} \cite{29,31}. Herein, we will summarize some of the research work on the application of gene-enhanced tissue engineering for these tissues according to the gene transfer approaches described above.

#### 2.2.1. Applications of \textit{ex vivo} approach

The \textit{ex vivo} approach was the initial effort toward developing somatic gene therapy. A large number of cell types have been proposed to be transduced by this approach \cite{32}.

As bone morphogenetic protein (BMP) is one of the most important cytokines that control the cellular events associated with bone formation and repair \cite{33}, variety of BMP-transduced cell types, including osteoblasts, bone marrow stromal, muscle-derived, periosteal, and fibroblastic cells, have shown to produce bone in ectopic sites \cite{34,41}. In 1999, Breitbart and Mason \textit{et al.} demonstrated that cultured rabbit periosteal cells transduced retrovirally with the bone morphogenetic protein 7 (BMP-7) gene could be produced, and polyglycolic acid (PGA) matrices seeded with these cells could repair critical-size rabbit cranial defects much better than the negative control-transduced cells/PGA, non-transduced cells/PGA or PGA alone \cite{7}. They used the similar scheme to transduce and culture periosteal-derived rabbit mesenchymal stem cells with the BMP-7 gene, and the PGA grafts containing these modified cells consistently showed complete or near complete bone and articular
cartilage regeneration at 8 and 12 weeks. This is the first report of articular cartilage regeneration using a combined gene therapy and tissue engineering approach [6]. Lou and collaborators showed that BMP-2-engineered allogenic mesenchymal stem cells repair critically sized rat femoral defects to the same degree as engineered autologous cells, if the allogenic group received short-term immunosuppressant therapy [62].

The ex vivo approaches in bone and cartilage gene-enhanced tissue engineering are not limited to BMP as expression of LIM mineralization protein-1 (LMP-1) and Runx2/Cbfa1 transcription factor promote bone formation in heterotopic and orthotopic sites [43-48].

Exposure of de-endothelialized vascular structures to blood flow will cause platelet adherence and thrombus formation. Bare synthetic vascular graft material is highly thrombogenic because of serum protein adherence and platelet deposition. Thus, seeding of genetically modified endothelial cells onto vascular grafts has emerged as a promising technique within the cardiovascular system. In 1989, Zwiebel et al. reported high levels of recombinant gene expression in rabbit endothelial cells [49]. In the same year, Wilson et al. implanted synthetic vascular grafts seeded with retrovirally transduced endothelial cells in a canine model [50]. The t-PA transduced baboon endothelial cells seeded onto collagen coated vascular grafts reduced platelet and fibrin deposition in baboon femoral arteriovenous shunts [51]. However, it is also reported that the proteolytic effects of the t-PA secreted by the transduced endothelial cells might diminish the cells’ ability to adhere to vascular graft material in vivo over time [52], which reminds the researchers to pay more attention to the nature of the recombinant gene products being delivered by seeded endothelial cells [25].

The ex vivo approach was also used in wound healing models by Breitbart et al. The human platelet-derived growth factor b (PDGF-B) gene was introduced into primary rat dermal cells in vitro. Seeding of the gene-modified cells onto PGA scaffold matrices and introduction into the rat model resulted in substantially increased fibroblast hypercellularity over control wounds at both 7 and 14 days posttreatment [8].

### 2.2.2. Applications of in vivo approach

In order to introduce DNA directly into tissues, different methods have been tried to locally deliver plasmid gene constructs. For example, DNA has been formulated in a liquid buffer (e.g. “naked DNA”) and with (proteo)liposome carriers [56, 57], has been encapsulated in controlled release synthetic polymer particles [58], has been incorporated into hydrogels [59] and sustained release polymer emulsions [60]. All the above methods belong to polymeric release, in which DNA is entrapped within the material and released into the environment, with release typically occurring through a combination of diffusion and polymer degradation [61].

As to the gene delivery in vivo in tissue engineering, substrate-mediated delivery was developed, in which DNA is concentrated at the delivery site and targeted to the cells that are adhered to the substrate [62, 63]. Cells cultured on the substrate can internalize the DNA either directly from the surface or by degrading the linkage between the vector and the material. The structural matrix in which DNA has been incorporated directly is called as gene activated matrices (GAM) [5, 11, 32, 61, 64, 65]. The matrices in GAM then act in a dual role of both structural support for cell growth and vehicle for controlled release of tissue inductive factors. The first GAM feasibility study involved direct plasmid-gene transfer to repair cells participating in bone repair in the adult rat [66]. GAMs with either a BMP-4 plasmid or a plasmid coding for a secreted fragment of parathryroid hormone (PTH) induced in a biological response of new bone filling the defect. Implantation of a two-plasmid GAM (BMP-4 plus PTH 1–34, which act synergistically) caused new bone to form faster than with either factor alone. This work showed for the first time that new bone will form rapidly in vivo following direct osteoinductive plasmid gene transfer to fibroblasts.

GAM system has been used in a variety of natural and synthetic materials for DNA delivery in different tissues. Collagen-based delivery of nonviral or viral DNA has been employed in models of bone [66-68], cartilage [69], and nerve regeneration [70], wound healing [71-73], muscle repair [74] and cardiovascular disease [75]. Porous poly(lactide-co-glycolide) (PLG) scaffolds releasing plasmid DNA were able to transfet cells within and around the scaffold, with sufficient expression of PDGF to promote tissue formation [76]. In summary, gene-enhanced tissue engineering studies have illustrated the potential for extending the production of growth factors locally. Adapting the gene strategies to control the expression of the signaling factors spatially (micrometers to millimeters) or temporally (days to months) may recreate the environmental complexity present during tissue formation, which will promote the efficacy of tissue engineering.

### 3. GENETICALLY ENGINEERING SCAFFOLD MATERIALS

As mentioned above, the scaffold used in tissue engineering acts to support cell colonization, migration, growth and differentiation, and often guides the development of the required tissue. Rutherford et al. showed that different scaffolds support in vivo bone formation to various degrees [77]. This study suggests that the nature and properties of the scaffold plays an
important role in bone engineering, and the scaffold can be engineered to help to optimize cell delivery and tissue formation.

The nature and biological fate of the scaffolds, which are usually natural or synthetic polymers, depends on their molecular architecture. The molecular weight, composition, sequence and stereochemistry of chemically synthesized polymers are usually heterogeneous and defined in terms of statistical distributions. With the progress of gene technology, genetic engineering methodology has enabled the synthesis of protein-based polymers with precisely controlled structures. In contrast to chemically synthesized poly(amino acids) and sequential polypeptides, the entire amino acid sequence of genetically engineered polymers is controlled at the DNA-level, leading to polymers with precisely defined, and potentially quite complex, sequences and structures. Protein-based polymers can be designed to incorporate a variety of functionalities, including responsiveness to microenvironmental stimuli, controlled biodegradation and the presentation of informational motifs for cellular and subcellular interactions. Varieties of polymers, such as Elastin-like polymers, silk-like polymers, silk–elastinlike block copolymers, coiled-coil and leucin-rich protein domains, $\beta$-sheet forming polymers, alanylglycine polymers and recombinant poly(glutamic acid) polymers, have been produced using the genetic engineering method. The genetically engineered protein-based polymers have been applied in blood vessel reconstruction to improve the attachment and spreading ability of the endothelial cells. Artificial extracellular matrix protein composed of a repeating unit structure (GVPGI)$_x$ and a cell-binding domain (designated CS5) derived from the natural extracellular matrix protein fibronectin were suggested as a vascular graft material. It was demonstrated that spreading of cells was enhanced on surfaces coated with [CS$_3$(GVPGI)$_{20}$]$_5$ when compared to surfaces coated with fibronectin.

Although no many reports can be found yet in the field of genetically engineered scaffold materials at present time, the authors suppose that it may become another attractive topic in advanced tissue engineering.

4. FINAL REMARKS

As a multidisciplinary research area that incorporates both biological and engineering principles, tissue engineering has the potential to develop widely with the fast evolvement in biology science. The confluence of molecular and cell biology, materials science and engineering provides the tools to create controllable microenvironments that mimic natural developmental processes and direct tissue formation for experimental and therapeutic applications. The results of recent efficacy studies provide evidence that delivery of certain stimulatory gene products can be used to elicit favorable biological responses in vivo. However, the development of gene technology in tissue engineering will have to experience more experiments and validation before it becomes a practical therapy method as there still exist many challenges and/or unclear understandings in this field of science.

E. Pennisi once pointed out that although genes have played biology's center stage for decades as the units of DNA that define the proteins needed for life, gene expression is not determined solely by the DNA code itself. Gene activity also depends on a host of so-called epigenetic phenomena and can be altered by proteins and RNA. Deeper understanding of the role of DNA with the evolvement of biology science will definitely improve the using of gene technology in tissue engineering radically.

The two major challenges facing gene technology in tissue engineering presently include the problem of identifying appropriate genes that are effective in tissue repair based on delineation of the protein needed for proper tissue function, and the reliable expression of the therapeutic gene for achieving effective repair of diseased or injured tissue in a durable manner. More sophisticated promoter systems may be incorporated to finely tune the transgenic expression process if the required quantity and time of expression can be determined. A sustained track record of safety and long-term clinical efficacy should be established prior to human testing, since many of the gene products implicated for use in treatment have the potential for generating significant side effects.

Considering the engineering of complex tissue architectures, such as those found in vascular networks and the nervous systems, the ability to regulate expression of one or more factors in time and space may be critical. Studies in these systems would also increase our understanding of the biology behind tissue formation, which would serve to identify how gene delivery can best augment the regenerative process. More sophisticated promoter systems may be incorporated to finely tune the transgenic expression process if the required quantity and time of expression can be determined. A sustained track record of safety and long-term clinical efficacy should be established prior to human testing, since many of the gene products implicated for use in treatment have the potential for generating significant side effects.

In summary, gene technology has shown a promising potential to be used in tissue engineering for the optimal tissue regeneration, yet, much work has to be carried out to consummate the knowledge and techniques in this field.

ACKNOWLEDGMENTS

We acknowledge the financial support from both the project No. 50402001 supported by National Natural Science Foundation of China, and the grant (code #: 06K1501-01620) from Center for Nanostructured Materials Technology under 21st Century Frontier R&D Program of the Ministry of Science and Technology, Korea.
REFERENCES


